Literature DB >> 29691234

Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation.

Cristiana Borrelli1,2, Biancamaria Ricci3, Elisabetta Vulpis1, Cinzia Fionda1, Maria Rosaria Ricciardi4, Maria Teresa Petrucci5, Laura Masuelli6, Agnese Peri1, Marco Cippitelli1, Alessandra Zingoni1, Angela Santoni7,8, Alessandra Soriani9.   

Abstract

Treatment of multiple myeloma (MM) cells with sublethal doses of genotoxic drugs leads to senescence and results in increased NK cell recognition and effector functions. Herein, we demonstrated that doxorubicin- and melphalan-treated senescent cells display increased expression of IL15, a cytokine involved in NK cell activation, proliferation, and maturation. IL15 upregulation was evident at the mRNA and protein level, both in MM cell lines and malignant plasma cells from patients' bone marrow (BM) aspirates. However, IL15 was detectable as a soluble cytokine only in vivo, thus indicating a functional role of IL15 in the BM tumor microenvironment. The increased IL15 was accompanied by enhanced expression of the IL15/IL15RA complex on the membrane of senescent myeloma cells, allowing the functional trans-presentation of this cytokine to neighboring NK cells, which consequently underwent activation and proliferation. We demonstrated that MM cell-derived exosomes, the release of which was augmented by melphalan treatment in senescent cells, also expressed IL15RA and IL15, and their interaction with NK cells in the presence of exogenous IL15 resulted in increased proliferation. Altogether, our data demonstrated that low doses of chemotherapeutic drugs, by inducing tumor cell senescence and a senescence-associated secretory phenotype, promoted IL15 trans-presentation to NK cells and, in turn, their activation and proliferation, thus enhancing NK cell-tumor immune surveillance and providing new insights for the exploitation of senescence-based cancer therapies. Cancer Immunol Res; 6(7); 860-9. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29691234     DOI: 10.1158/2326-6066.CIR-17-0604

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  25 in total

Review 1.  Emerging role of exosomes in hematological malignancies.

Authors:  Sureshbabu Ram Kumar Pandian; Kevin Kumar Vijayakumar; Selvaraj Kunjiappan; Ewa Babkiewicz; Piotr Maszczyk
Journal:  Clin Exp Med       Date:  2022-07-07       Impact factor: 3.984

Review 2.  Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword.

Authors:  Anthony M Battram; Mireia Bachiller; Beatriz Martín-Antonio
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

3.  Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.

Authors:  Elisabetta Vulpis; Helena Stabile; Alessandra Soriani; Cinzia Fionda; Maria Teresa Petrucci; Elena Mariggio'; Maria Rosaria Ricciardi; Marco Cippitelli; Angela Gismondi; Angela Santoni; Alessandra Zingoni
Journal:  Cancers (Basel)       Date:  2018-11-29       Impact factor: 6.639

Review 4.  Exosomes in Immune Regulation.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Noncoding RNA       Date:  2021-01-08

Review 5.  The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases.

Authors:  Lorenzo Cuollo; Fabrizio Antonangeli; Angela Santoni; Alessandra Soriani
Journal:  Biology (Basel)       Date:  2020-12-21

Review 6.  Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T-cells and tumour cells.

Authors:  Filippo Del Vecchio; Verena Martinez-Rodriguez; Monique Schukking; Alexander Cocks; Elisabetta Broseghini; Muller Fabbri
Journal:  J Extracell Vesicles       Date:  2021-04-01

Review 7.  Exosomal Non-coding RNAs-Mediated Crosstalk in the Tumor Microenvironment.

Authors:  Qi Chen; Yuefeng Li; Yueqin Liu; Wenlin Xu; Xiaolan Zhu
Journal:  Front Cell Dev Biol       Date:  2021-04-12

Review 8.  Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.

Authors:  Kerry S Campbell; Adam D Cohen; Tatiana Pazina
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

Review 9.  Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response.

Authors:  Elisabetta Vulpis; Alessandra Soriani; Cristina Cerboni; Angela Santoni; Alessandra Zingoni
Journal:  Int J Mol Sci       Date:  2019-01-31       Impact factor: 5.923

Review 10.  Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration.

Authors:  Dae Hyun Ha; Hyun-Keun Kim; Joon Lee; Hyuck Hoon Kwon; Gyeong-Hun Park; Steve Hoseong Yang; Jae Yoon Jung; Hosung Choi; Jun Ho Lee; Sumi Sung; Yong Weon Yi; Byong Seung Cho
Journal:  Cells       Date:  2020-05-07       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.